Related references
Note: Only part of the references are listed.Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature
Michael J. Allen et al.
JOURNAL OF CLINICAL PATHOLOGY (2023)
Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with advanced pancreatic adenocarcinoma (NCT03665441).
Pascal Hammel et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety
John H Strickler et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation
Tanios S. Bekaii-Saab et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Relevance of biopsy-derived pancreatic organoids in the development of efficient transcriptomic signatures to predict adjuvant chemosensitivity in pancreatic cancer
R. Nicolle et al.
TRANSLATIONAL ONCOLOGY (2022)
Hallmarks of Cancer: New Dimensions
Douglas Hanahan
CANCER DISCOVERY (2022)
Novel Insights on the Use of L-Asparaginase as an Efficient and Safe Anti-Cancer Therapy
Maaike Van Trimpont et al.
CANCERS (2022)
Targeting autophagy in disease: established and new strategies
Muhammed Kocak et al.
AUTOPHAGY (2022)
Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma
Philip A. Philip et al.
CLINICAL CANCER RESEARCH (2022)
Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer
Rom Leidner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Translational advances in pancreatic ductal adenocarcinoma therapy
Abdel Nasser Hosein et al.
NATURE CANCER (2022)
The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells
Pau Munoz-Guardiola et al.
AUTOPHAGY (2021)
Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications
Claudio Luchini et al.
GUT (2021)
Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer
Stephan B. Dreyer et al.
GASTROENTEROLOGY (2021)
TGFβ-Directed Therapeutics: 2020
Beverly A. Teicher
PHARMACOLOGY & THERAPEUTICS (2021)
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition
Marco H. Hofmann et al.
CANCER DISCOVERY (2021)
CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma
Deepak Raj et al.
CLINICAL CANCER RESEARCH (2021)
The potential targeted drugs for fusion genes including NRG1 in pancreatic cancer
Kumiko Umemoto et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.
Talia Golan et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor
Xiaolun Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma
R. Nicolle et al.
ANNALS OF ONCOLOGY (2021)
Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study
M. Tempero et al.
ANNALS OF ONCOLOGY (2021)
Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development
Xing Huang et al.
MOLECULAR CANCER (2021)
KRAS mutation in pancreatic cancer
Ji Luo
SEMINARS IN ONCOLOGY (2021)
Microbiome and pancreatic ductal adenocarcinoma
Annemilai Tijeras-Raballand et al.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY (2021)
Targeting the DNA replication stress phenotype of KRAS mutant cancer cells
Tara Al Zubaidi et al.
SCIENTIFIC REPORTS (2021)
Targeting KRAS G12D Mutant for the Potential Treatment of Pancreatic Cancer
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2021)
Pancreatic Cancer Meets Human Microbiota: Close Encounters of the Third Kind
Tatjana Arsenijevic et al.
CANCERS (2021)
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort
U. Peretti et al.
ESMO OPEN (2021)
Patient-derived xenograft models of BRCA-associated pancreatic cancers
Talia Golan et al.
ADVANCED DRUG DELIVERY REVIEWS (2021)
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
D. J. McGrail et al.
ANNALS OF ONCOLOGY (2021)
Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2
Kim A. Reiss et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes
Anna M. Varghese et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Estimated Projection of US Cancer Incidence and Death to 2040
Lola Rahib et al.
JAMA NETWORK OPEN (2021)
Mesothelin is Commonly Expressed in Pancreatic Adenocarcinoma but Unrelated to Cancer Aggressiveness
Soren Weidemann et al.
CANCER INVESTIGATION (2021)
Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer.
David S. Hong et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions.
Alison M. Schram et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Pancreatic Cancer Progression in a Patient With Lynch Syndrome Receiving Immunotherapy: A Cautionary Tale
Yifan Wang et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
KRAS mutation: from undruggable to druggable in cancer
Lamei Huang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Targeting FAK in anticancer combination therapies
John C. Dawson et al.
NATURE REVIEWS CANCER (2021)
Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types
Nadia Terranova et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2021)
Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion
Hong Jiang et al.
GUT (2020)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer
Christopher Nevala-Plagemann et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial
Pascal Hammel et al.
EUROPEAN JOURNAL OF CANCER (2020)
Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation
Eileen M. O'Reilly et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
David S. Hong et al.
LANCET ONCOLOGY (2020)
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
Louis Buscail et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?
Alice Bradbury et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer
Michael Overman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer
Grainne M. O'Kane et al.
CLINICAL CANCER RESEARCH (2020)
Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection
Wungki Park et al.
CLINICAL CANCER RESEARCH (2020)
New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma
Ritu Raj Singh et al.
DRUGS (2020)
Cancer vaccines: Targeting KRAS-driven cancers
Ying Zhang et al.
EXPERT REVIEW OF VACCINES (2020)
The human tumor microbiome is composed of tumor type-specific intracellular bacteria
Deborah Nejman et al.
SCIENCE (2020)
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
Vito Amodio et al.
CANCER DISCOVERY (2020)
Enhancing the Efficacy of CAR T Cells in the Tumor Microenvironment of Pancreatic Cancer
Janina Henze et al.
CANCERS (2020)
Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I
Keisuke Yamamoto et al.
NATURE (2020)
Pancreatic cancer stroma: an update on therapeutic targeting strategies
Abdel N. Hosein et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
PDAC resistance to immunotherapy - a role for autophagy?
Jordan Hindson
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
The forefront of ovarian cancer therapy: update on PARP inhibitors
M. R. Mirza et al.
ANNALS OF ONCOLOGY (2020)
Immunotherapy for pancreatic cancer: A 2020 update
Dimitrios Schizas et al.
CANCER TREATMENT REVIEWS (2020)
Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer
Remy Nicolle et al.
EBIOMEDICINE (2020)
Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
Michelle McMullen et al.
CANCERS (2020)
Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Metastatic Pancreatic Cancer: ASCO Guideline Update
Davendra P. S. Sohal et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)
D. J. Renouf et al.
ANNALS OF ONCOLOGY (2020)
NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents
J. Laskin et al.
ANNALS OF ONCOLOGY (2020)
Molecular Targeting of a BRAF Mutation in Pancreatic Ductal Adenocarcinoma: Case Report and Literature Review
An-Katrien Seghers et al.
TARGETED ONCOLOGY (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer
Vincent Picozzi et al.
ESMO OPEN (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Challenges in Ras therapeutics in pancreatic cancer
Minsig Choi et al.
SEMINARS IN CANCER BIOLOGY (2019)
Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer
Matthew B. Yurgelun et al.
GENETICS IN MEDICINE (2019)
Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma
Evan J. Walker et al.
FAMILIAL CANCER (2019)
Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma
Deepak Raj et al.
GUT (2019)
Progress in targeting RAS with small molecule drugs
Frank McCormick
BIOCHEMICAL JOURNAL (2019)
Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers
Aatur D. Singhi et al.
GASTROENTEROLOGY (2019)
Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313
Ramesh K. Ramanathan et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS
Jing Wang et al.
MODERN PATHOLOGY (2019)
Detection of NRG1 Gene Fusions in Solid Tumors
Sushma Jonna et al.
CLINICAL CANCER RESEARCH (2019)
NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma
Martin R. Jones et al.
CLINICAL CANCER RESEARCH (2019)
A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.
Davide Melisi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Neuregulin 1 Fusion-Positive NSCLC
Misako Nagasaka et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer A Phase 2 Randomized Clinical Trial
Thomas B. Karasic et al.
JAMA ONCOLOGY (2019)
Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers
Andrew R. Haas et al.
MOLECULAR THERAPY (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial
Eileen M. O'Reilly et al.
JAMA ONCOLOGY (2019)
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer
Miriam Molina-Arcas et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions
Emiliano Cocco et al.
CANCER RESEARCH (2019)
Fusion Kinases Identified by Genomic Analyses of Sporadic Microsatellite Instability-High Colorectal Cancers
Kazuhito Sato et al.
CLINICAL CANCER RESEARCH (2019)
Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer
Alicia Latham et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma
Cindy Neuzillet et al.
JOURNAL OF PATHOLOGY (2019)
State-of-the-art strategies for targeting the DNA damage response in cancer
Patrick G. Pilie et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Systemic treatment of pancreatic cancer revisited
Michel Ducreux et al.
SEMINARS IN ONCOLOGY (2019)
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Kevin K. Lin et al.
CANCER DISCOVERY (2019)
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors
David Hong et al.
ONCOLOGY (2019)
Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations
Zishuo I. Hu et al.
CLINICAL CANCER RESEARCH (2018)
Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins
Ed S. Kheder et al.
CLINICAL CANCER RESEARCH (2018)
Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma
Maeve A. Lowery et al.
EUROPEAN JOURNAL OF CANCER (2018)
Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial
Gregory L. Beatty et al.
GASTROENTEROLOGY (2018)
Prevalence of Microsatellite Instability in Intraductal Papillary Mucinous Neoplasms of the Pancreas
Renato M. Lupinacci et al.
GASTROENTEROLOGY (2018)
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study
John D. Hainsworth et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
CAR T cell immunotherapy for human cancer
Carl H. June et al.
SCIENCE (2018)
Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
Marc Hilmi et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
CAR-T cells: the long and winding road to solid tumors
Maria Michela D'Aloia et al.
CELL DEATH & DISEASE (2018)
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine
Andrew J. Aguirre et al.
CANCER DISCOVERY (2018)
Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
Herve Tiriac et al.
CANCER DISCOVERY (2018)
NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer
Christoph Heining et al.
CANCER DISCOVERY (2018)
Molecular Profiling of Pancreatic Cancer Patients-Response
Michael J. Pishvaian et al.
CLINICAL CANCER RESEARCH (2018)
Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features
Francesco Puleo et al.
GASTROENTEROLOGY (2018)
Inhibitors of G12C Mutant Ras Proteins for the Treatment of Cancers
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2018)
A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma (PDAC) (MOBILITY-002 Trial, NCT02428270).
Kyaw Lwin Aung et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma
Annika L. Windon et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2018)
Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial
Kyaw L. Aung et al.
CLINICAL CANCER RESEARCH (2018)
GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer
Paola Martinelli et al.
GUT (2017)
ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells
Stephanie A. Yazinski et al.
GENES & DEVELOPMENT (2017)
Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial
Angela Alistar et al.
LANCET ONCOLOGY (2017)
Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas
Cindy Neuzillet et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine
Leore T. Geller et al.
SCIENCE (2017)
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord et al.
SCIENCE (2017)
Pancreatic Cancer in Lynch Syndrome Patients
Luis Bujanda et al.
JOURNAL OF CANCER (2017)
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity
Fiona C. Thistlethwaite et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study
B. Schultheis et al.
ANNALS OF ONCOLOGY (2017)
Expanding the Scope of Electrophiles Capable of Targeting K-Ras Oncogenes
Lynn M. McGregor et al.
BIOCHEMISTRY (2017)
RAS Proteins and Their Regulators in Human Disease
Dhirendra K. Simanshu et al.
CELL (2017)
Targeting neoantigens to augment antitumour immunity
Mark Yarchoan et al.
NATURE REVIEWS CANCER (2017)
Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer
Christopher J. Habrook et al.
CANCER CELL (2017)
The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase
Tatiana Erazo et al.
CLINICAL CANCER RESEARCH (2016)
Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis
Shuang G. Zhao et al.
LANCET ONCOLOGY (2016)
Critical role of oncogenic KRAS in pancreatic cancer
Jiang Liu et al.
MOLECULAR MEDICINE REPORTS (2016)
Genomic analyses identify molecular subtypes of pancreatic cancer
Peter Bailey et al.
NATURE (2016)
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
F. Cardoso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Piro Lito et al.
SCIENCE (2016)
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
Matthew P. Patricelli et al.
CANCER DISCOVERY (2016)
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
Junko Murai et al.
ONCOTARGET (2016)
MAESTRO: A randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC)
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The biology and function of fibroblasts in cancer
Raghu Kalluri
NATURE REVIEWS CANCER (2016)
Ibrutinib Exerts Potent Antifibrotic and Antitumor Activities in Mouse Models of Pancreatic Adenocarcinoma
D. Masso-Valles et al.
CANCER RESEARCH (2015)
Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity
Alan Serrels et al.
CELL (2015)
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer
Daniel V. T. Catenacci et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma
Spring Holter et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial
Sil Kordes et al.
LANCET ONCOLOGY (2015)
Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism
RushikaM. Perera et al.
NATURE (2015)
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Agnieszka K. Witkiewicz et al.
NATURE COMMUNICATIONS (2015)
Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival
Berna C. Oezdemir et al.
CANCER CELL (2014)
Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
Andrew D. Rhim et al.
CANCER CELL (2014)
Targeting ATR in DNA damage response and cancer therapeutics
Emmanouil Fokas et al.
CANCER TREATMENT REVIEWS (2014)
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
Gary Middleton et al.
LANCET ONCOLOGY (2014)
Drugging the undruggable RAS: Mission Possible?
Adrienne D. Cox et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104
S. Boeck et al.
BRITISH JOURNAL OF CANCER (2013)
ATR Inhibition Broadly Sensitizes Ovarian Cancer Cells to Chemotherapy Independent of BRCA Status
Catherine J. Huntoon et al.
CANCER RESEARCH (2013)
Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer
Takeshi Ogura et al.
JOURNAL OF GASTROENTEROLOGY (2013)
KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer
Stefan Boeck et al.
JOURNAL OF GASTROENTEROLOGY (2013)
Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer
Dung T. Le et al.
JOURNAL OF IMMUNOTHERAPY (2013)
Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy in Vivo Antitumor Activity
Kevin M. Foote et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Jonathan M. Ostrem et al.
NATURE (2013)
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Jaekyoung Son et al.
NATURE (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer
Albrecht Neesse et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Mechanisms of Resistance to PARP Inhibitors-Three and Counting
Tito Fojo et al.
CANCER DISCOVERY (2013)
Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
Haoqiang Ying et al.
CELL (2012)
T Cells That Target Carcinoembryonic Antigen Eradicate Orthotopic Pancreatic Carcinomas Without Inducing Autoimmune Colitis in Mice
Markus Chmielewski et al.
GASTROENTEROLOGY (2012)
New biomarkers and targets in pancreatic cancer and their application to treatment
Eithne Costello et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2012)
Clinical implications of mismatched repair gene promoter methylation in pancreatic cancer
M. Li et al.
MEDICAL ONCOLOGY (2012)
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
Yuhui Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Lapatinib and Gemcitabine for Metastatic Pancreatic Cancer A Phase II Study
Howard Safran et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent Manner
Oren Gilad et al.
CANCER RESEARCH (2010)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
Risk of Pancreatic Cancer in Families With Lynch Syndrome
Fay Kastrinos et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
Kenneth P. Olive et al.
SCIENCE (2009)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Enhanced expression of asparagine synthetase under glucose-deprived conditions protects pancreatic cancer cells from apoptosis induced by glucose deprivation and cisplatin
Hongyan Cui et al.
CANCER RESEARCH (2007)
Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study
S. L. Bernhardt et al.
BRITISH JOURNAL OF CANCER (2006)
Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis
R Hassan et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2005)
Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu
H Safran et al.
CANCER INVESTIGATION (2004)
Share Paper
